FindTrial
Sign In

Clinical Evaluation of NK211 for Ovarian Cancer

Clinical Evaluation of NK211 for Ovarian Cancer

Status
Unknown
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220963
Enrollment
Unknown
Registered
2010-01-13
Start date
2010-01-13
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent ovarian cancer

Interventions

investigational material(s) Generic name etc : NK211 INN of investigational material : Therapeutic category code : 424 Antineoplastic preparations extracted from plants Dosage and Administration for

Sponsors

Nippon Kayaku Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1)Histologic or cytologic diagnosis of ovarian cancer 2)Relapse-patients treated with standard chemotherapy 3)Patient whose prior therapy other than medication doesn't influence evaluation. 4)ECOG PS 0-2

Exclusion criteria

Exclusion criteria:

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026